Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.85 |
| ▸ | MPO | P05164 | 5/20 | 0.81 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.69 |
| ▸ | HTR1D | P28221 | 1/20 | 0.66 |
| ▸ | HTR1B | P28222 | 1/20 | 0.66 |
| ▸ | HTR7 | P34969 | 5/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL739944 | 0.96 | HTR1A (0.79) | HTR1AMPOSLC6A4HTR1DHTR1B | |
| SCHEMBL9635445 | 0.84 | MPO (0.73) | HTR1AMPOSLC6A4 | |
| SCHEMBL10072404 | 0.82 | HTR1A (0.81) | HTR1AMPOSLC6A4HTR7KCNH2 | |
| SCHEMBL17249759 | 0.82 | HTR1A (0.67) | HTR1AHTR1DHTR1B | |
| SCHEMBL30468393 | 0.82 | HTR1A (0.67) | HTR1AHTR1DHTR1B | |
| SCHEMBL8557344 | 0.82 | HTR1A (0.76) | HTR1AMPOSLC6A4HTR7KCNH2 | |
| SCHEMBL26508398 | 0.81 | MPO (0.94) | HTR1AMPOSLC6A4HTR1DHTR1B | |
| SCHEMBL1377300 | 0.81 | HTR1A (0.83) | HTR1ASLC6A4HTR1DHTR1BHTR7 | |
| SCHEMBL733997 | 0.81 | MPO (1.00) | HTR1AMPOHTR1DHTR1BHTR7 | |
| SCHEMBL29515418 | 0.80 | MPO (0.80) | HTR1AMPOSLC6A4HTR7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015014256-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-02-05 | — | — | WO | disclosed |
| US-20090281114-A1 | INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION | FABRE-KRAMER PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281114-A1 | INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION | FABRE-KRAMER PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| EP-0714896-A1 | INDOL DERIVATIVES USEFUL FOR THE TREATMENT OF MIGRAINE, COMPOSITION AND UTILIZATION | VITA-INVEST, S.A. (ES) | 1996-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281114-A1 | INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION | HTR5A, TPH2, IDO2 | HTR1A 15/4885MPO 592/4885SLC6A4 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.